Abraham Morgentaler

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Wide variability in laboratory reference values for serum testosterone
    Stephen Lazarou
    Harvard Medical School, Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Sex Med 3:1085-9. 2006
  2. doi request reprint The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men
    Ernani Luis Rhoden
    Department of Urology, Federal Foundation of Medical Sciences of Porto Alegre, Porto Alegre, Brazil
    J Urol 179:1741-4. 2008
  3. doi request reprint Testosterone therapy in men with prostate cancer: scientific and ethical considerations
    Abraham Morgentaler
    Men s Health Boston and the Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Urol 189:S26-33. 2013
  4. ncbi request reprint Commentary: Guideline for male testosterone therapy: a clinician's perspective
    Abraham Morgentaler
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Clin Endocrinol Metab 92:416-7. 2007
  5. ncbi request reprint Testosterone therapy for men at risk for or with history of prostate cancer
    Abraham Morgentaler
    Men s Health Boston Harvard Medical School, One Brookline Place, Suite 624, Brookline, MA 02445, USA
    Curr Treat Options Oncol 7:363-9. 2006
  6. ncbi request reprint Testosterone and prostate cancer: an historical perspective on a modern myth
    Abraham Morgentaler
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Eur Urol 50:935-9. 2006
  7. doi request reprint Testosterone and prostate cancer: what are the risks for middle-aged men?
    Abraham Morgentaler
    Men s Health Boston, One Brookline Place, Suite 624, Brookline, MA 02445, USA
    Urol Clin North Am 38:119-24. 2011
  8. ncbi request reprint Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less
    Abraham Morgentaler
    Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Urology 68:1263-7. 2006
  9. ncbi request reprint Testosterone replacement therapy and prostate cancer
    Abraham Morgentaler
    Men s Health Boston, Brookline, MA, USA
    Urol Clin North Am 34:555-63, vii. 2007
  10. ncbi request reprint Rapidly shifting concepts regarding androgens and prostate cancer
    Abraham Morgentaler
    Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston USA
    ScientificWorldJournal 9:685-90. 2009

Collaborators

Detail Information

Publications53

  1. ncbi request reprint Wide variability in laboratory reference values for serum testosterone
    Stephen Lazarou
    Harvard Medical School, Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Sex Med 3:1085-9. 2006
    ..The laboratory determination of testosterone levels consistent with a diagnosis of hypogonadism is complicated by the availability of multiple testosterone assays and varying reference ranges...
  2. doi request reprint The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men
    Ernani Luis Rhoden
    Department of Urology, Federal Foundation of Medical Sciences of Porto Alegre, Porto Alegre, Brazil
    J Urol 179:1741-4. 2008
    ..We determined whether the ratio of serum testosterone to prostate specific antigen might provide diagnostic value regarding the risk of prostate cancer in a population of hypogonadal men undergoing prostate biopsy...
  3. doi request reprint Testosterone therapy in men with prostate cancer: scientific and ethical considerations
    Abraham Morgentaler
    Men s Health Boston and the Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Urol 189:S26-33. 2013
    ..Pertinent literature regarding the potential use of testosterone therapy in men with prostate cancer is reviewed and synthesized...
  4. ncbi request reprint Commentary: Guideline for male testosterone therapy: a clinician's perspective
    Abraham Morgentaler
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Clin Endocrinol Metab 92:416-7. 2007
  5. ncbi request reprint Testosterone therapy for men at risk for or with history of prostate cancer
    Abraham Morgentaler
    Men s Health Boston Harvard Medical School, One Brookline Place, Suite 624, Brookline, MA 02445, USA
    Curr Treat Options Oncol 7:363-9. 2006
    ..Although still controversial, there appears to be little reason to withhold TRT from men with favorable outcomes after definitive treatment for PCa. Monitoring with PSA and digital rectal examination at regular intervals is recommended...
  6. ncbi request reprint Testosterone and prostate cancer: an historical perspective on a modern myth
    Abraham Morgentaler
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Eur Urol 50:935-9. 2006
    ..To review the historical origins and current evidence for the belief that testosterone (T) causes prostate cancer (pCA) growth...
  7. doi request reprint Testosterone and prostate cancer: what are the risks for middle-aged men?
    Abraham Morgentaler
    Men s Health Boston, One Brookline Place, Suite 624, Brookline, MA 02445, USA
    Urol Clin North Am 38:119-24. 2011
    ..This apparent paradox is explained by the Saturation Model, which posits a finite capacity of androgen to stimulate PCa growth. Modern studies indicate no increased risk of PCa among men with serum T in the therapeutic range...
  8. ncbi request reprint Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less
    Abraham Morgentaler
    Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Urology 68:1263-7. 2006
    ..To determine the prevalence of prostate cancer in hypogonadal men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or less...
  9. ncbi request reprint Testosterone replacement therapy and prostate cancer
    Abraham Morgentaler
    Men s Health Boston, Brookline, MA, USA
    Urol Clin North Am 34:555-63, vii. 2007
    ..A saturation model is proposed that is consistent with regression of cancer when T is reduced to castrate levels and with lack of observed growth when serum T is increased...
  10. ncbi request reprint Rapidly shifting concepts regarding androgens and prostate cancer
    Abraham Morgentaler
    Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston USA
    ScientificWorldJournal 9:685-90. 2009
    ..It will be interesting to see what changes will occur in this rapidly changing field over the next several years...
  11. doi request reprint Testosterone and prostate safety
    Abraham Morgentaler
    Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02445, USA
    Front Horm Res 37:197-203. 2009
    ..Given that the population at risk for T deficiency overlaps with the population at risk for prostate cancer, it is strongly recommended that men undergoing T therapy undergo regular monitoring for prostate cancer...
  12. ncbi request reprint A 66-year-old man with sexual dysfunction
    Abraham Morgentaler
    Men s Health Boston, Mass 02445, USA
    JAMA 291:2994-3003. 2004
  13. doi request reprint Testosterone deficiency
    Abdulmaged M Traish
    Department of Biochemistry, Division of Urology, Boston University School of Medicine, Mass, USA
    Am J Med 124:578-87. 2011
    ..This review examines a host of studies, with practical recommendations for diagnosis of TD and T repletion in middle-aged and older men, including an analysis of treatment modalities and areas of concerns and uncertainty...
  14. ncbi request reprint Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility
    Ravi Kacker
    Men s Health Boston, Brookline, Massachusetts, and New York Medical College JZ, Valhalla, New York
    J Urol 191:1072-6. 2014
    ..Testosterone deficiency is a known risk factor for osteopenia and osteoporosis in older men. Less is known about the impact of testosterone deficiency on bone mineral density in younger men...
  15. ncbi request reprint The evaluation and management of testosterone deficiency: the new frontier in urology and men's health
    William P Conners
    Men s Health Boston, Harvard Medical School, One Brookline Place, Suite 624, Brookline, MA, 02445, USA
    Curr Urol Rep 14:557-64. 2013
    ..Overall, TTh is relatively safe but the risks, such as erythrocytosis, makes long-term monitoring mandatory. The evidence does not support concerns regarding cardiovascular and prostate cancer risks. ..
  16. doi request reprint Is testosterone a friend or a foe of the prostate?
    Emmanuele A Jannini
    Department of Experimental Medicine, University of L Aquila, L Aquila, Italy Men s Health Boston, Harvard Medical School, Boston, MA, USA
    J Sex Med 8:946-55. 2011
    ..Furthermore, currently adequately powered and optimally designed long-term prostate disease data are not available to determine if there is an additional risk from normal T values in cured patients for PCa...
  17. ncbi request reprint Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia
    Ernani Luis Rhoden
    Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Urol 170:2348-51. 2003
    ..We evaluated prostatic changes in hypogonadal men with and without high grade prostatic intraepithelial neoplasia (PIN), which is considered a prostatic precancerous lesion, after 1 year of TRT...
  18. ncbi request reprint Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone
    Luis Reyes-Vallejo
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Sex Med 4:1757-62. 2007
    ..Testosterone replacement therapy (TRT) has been shown to be beneficial for men with hypogonadism. However, it is unknown how well hypogonadal men respond to TRT based on the severity of testosterone deficiency...
  19. doi request reprint Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth
    Abraham Morgentaler
    Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Eur Urol 55:310-20. 2009
    ..The traditional belief that prostate cancer (PCa) growth is dependent on serum testosterone (T) level has been challenged by recent negative studies in noncastrated men...
  20. doi request reprint Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer
    Abraham Morgentaler
    Harvard Medical School, Urology, Brookline, MA, USA
    J Sex Med 6:574-7. 2009
    ..However, the traditional view regarding the relationship of T to PCa has come under new scrutiny, with recent reports suggesting that PCa growth may not be greatly affected by variations in serum T within the near-physiologic range...
  21. doi request reprint Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency
    Ravi Kacker
    Beth Israel Deaconess Medical Center, Harvard Medical School, Urology, Boston, MA 02116, USA
    J Sex Med 9:1681-96. 2012
    ..The role of estrogens in male sexual function and the pathogenesis of testosterone deficiency remain controversial and poorly understood...
  22. ncbi request reprint Risks of testosterone-replacement therapy and recommendations for monitoring
    Ernani Luis Rhoden
    Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, USA
    N Engl J Med 350:482-92. 2004
  23. ncbi request reprint Hypogonadism in the man with erectile dysfunction: what to look for and when to treat
    Stephen Lazarou
    Men s Health Boston, One Brookline Place 624, Brookline, MA 02445, USA
    Curr Urol Rep 6:476-81. 2005
    ..Hematocrit or hemoglobin also should be obtained regularly due to the risk of erythrocytosis. Awareness of the benefits of TRT in the man with ED may improve clinical outcomes...
  24. ncbi request reprint Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice
    Ernani Luis Rhoden
    Men s Health Boston, Division of Urology, Harvard Medical School, Boston, MA, USA
    J Sex Med 7:277-83. 2010
    ....
  25. doi request reprint Testosterone therapy in men with untreated prostate cancer
    Abraham Morgentaler
    Men s Health Boston, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Urol 185:1256-60. 2011
    ..Recent evidence has called this paradigm into question. In this study we investigate the effect of testosterone therapy in men with untreated prostate cancer...
  26. ncbi request reprint Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population
    Sergio A Moreno
    Men s Health Boston, Harvard Medical School, Boston, MA, USA
    J Sex Med 7:1948-53. 2010
    ..Calculated FT (cFT), derived from total testosterone (TT) and sex-hormone binding globulin (SHBG) values has been recommended in its place. There are limited data comparing aFT and cFT in clinical populations...
  27. ncbi request reprint Technical advances in penile prostheses
    Stephen Lazarou
    Harvard Medical School, Beth Israel Deaconess Medical Center, Division of Urology, Boston, MA, USA
    J Long Term Eff Med Implants 16:235-47. 2006
    ..These advances make the penile prosthesis an excellent option for the treatment of ED, particularly for men who fail oral therapy...
  28. doi request reprint Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer
    Abraham Morgentaler
    Men s Health Boston, Harvard Medical School, Boston, MA 02445, USA
    J Sex Med 5:1834-40. 2008
    ..A long-standing belief is that higher testosterone (T) will increase the risk of prostate cancer (PCa), yet recent studies do not support this view...
  29. doi request reprint Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy
    William Conners
    Men s Health Boston, Beth Israel Deaconess Medical Center Harvard University Medical School, Division of Urology, Boston, MA 02445, USA
    J Sex Med 8:3465-70. 2011
    ..While this allows additional pellets to be inserted more easily, and increased space to place those pellets further from the skin incision, it minimally increases the surgical procedure...
  30. ncbi request reprint Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design
    Abraham Morgentaler
    Harvard Medical School, Brookline, MA, USA
    J Sex Med 3:492-503. 2006
    ..A secondary objective was to demonstrate the efficacy and safety of tadalafil 20 mg in various populations of men with ED...
  31. ncbi request reprint Testosterone therapy in men with prostate cancer: scientific and ethical considerations
    Abraham Morgentaler
    Men s Health Boston and the Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Urol 181:972-9. 2009
    ..Pertinent literature regarding the potential use of testosterone therapy in men with prostate cancer is reviewed and synthesized...
  32. doi request reprint Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship
    Sergio A Moreno
    Harvard Medical School, Boston, MA, USA
    J Sex Med 6:1729-35. 2009
    ..As testosterone (T) has been shown to influence wound healing, and serum T declines in the age group at risk for Peyronie's disease (PD), we explored the possibility that low serum T may be associated with PD...
  33. ncbi request reprint Phleboliths in varicoceles presenting as spermatic cord mass
    Stephen Lazarou
    Harvard Medical School, Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Fertil Steril 86:219.e21-2. 2006
    ..To discuss the diagnosis and management of phleboliths in the dilated veins of a varicocele...
  34. ncbi request reprint Testosterone replacement therapy and prostate risks: where's the beef?
    Abraham Morgentaler
    Division of Urology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Can J Urol 13:40-3. 2006
    ..These results argue against an increased risk of prostate cancer with testosterone replacement therapy...
  35. ncbi request reprint Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions
    Abraham Morgentaler
    Men s Health Boston, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Sex Med 11:1636-45. 2014
    ..Despite increasing use of testosterone therapy (TTh) for men with testosterone deficiency (TD), there remains uncertainty determining who is a candidate for treatment...
  36. doi request reprint Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy
    Stefania Di Sante
    Men s Health Boston, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Sex Med 9:585-93. 2012
    ..The prognostic value of serum total testosterone (TT) prior to treatment has not been investigated...
  37. doi request reprint A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion
    Andrew R McCullough
    Albany Medical College, Albany, NY 12208, USA
    J Sex Med 9:594-601. 2012
    ..Six academic institutions collaborated and combined their databases to more fully characterize serum testosterone levels after the pellet implantations...
  38. ncbi request reprint Erectile dysfunction
    Ernani Luis Rhoden
    Harvard Medical School, Boston, MA, USA
    J Long Term Eff Med Implants 13:519-28. 2003
    ..This review addresses the etiology, epidemiology, diagnosis, and treatment of erectile dysfunction in light of the remarkable advances in the field...
  39. ncbi request reprint The value of pituitary magnetic resonance imaging in men with hypogonadism
    Ernani Luis Rhoden
    Division of Urology, Beth Israel Deaconess Medical Center, Men s Health Boston, One Brookline Place, Suite 624, Brookline, MA 02445, USA
    J Urol 170:795-8. 2003
    ..We assessed the usefulness of magnetic resonance imaging (MRI) of the brain in the evaluation of hypogonadal men with a variety of endocrine patterns...
  40. doi request reprint Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study
    Abraham Morgentaler
    Men s Health Boston, Brookline, Massachusetts 02445, USA
    J Urol 180:2307-13. 2008
    ..We determined the pharmacokinetics and safety of 750 mg long acting testosterone undecanoate given intramuscularly at 0, 4 and 14 weeks to men with hypogonadism...
  41. doi request reprint Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population
    Ravi Kacker
    Men s Health Boston, Brookline, MA, USA and
    Aging Male 16:164-8. 2013
    ..Here, we evaluate the agreement between the radioimmunoassay (RIA) and calculated FT (cFT) versus equilibrium dialysis (EqD), considered the gold standard...
  42. doi request reprint The effect of aging on spermatogenesis and pregnancy outcomes
    Stephen Lazarou
    Division of Urology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Urol Clin North Am 35:331-9, xi. 2008
    ..This article reviews the available data on this topic, with an eye toward providing a basis for clinical counseling of the older man who wishes to have a child...
  43. ncbi request reprint Y chromosome microdeletions and male infertility: who should be tested and why?
    Luis Reyes-Vallejo
    Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
    BJU Int 97:441-3. 2006
  44. ncbi request reprint New concepts regarding the relationship of testosterone and prostate cancer
    Abraham Morgentaler
    Future Oncol 3:123-6. 2007
  45. ncbi request reprint Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove
    Abraham Morgentaler
    J Urol 175:1572; author reply 1573-4. 2006
  46. ncbi request reprint The association of time of day and serum testosterone concentration in a large screening population
    E David Crawford
    Surgery and Radiation Oncology, Section of Urologic Oncology, UCHSC, Aurora, CO, USA
    BJU Int 100:509-13. 2007
    ....
  47. ncbi request reprint Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80
    Abraham Morgentaler
    Eur Urol 52:292; author reply 293-4. 2007
  48. ncbi request reprint Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship
    Abraham Morgentaler
    Eur Urol 52:623-5. 2007
  49. ncbi request reprint Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy
    Holly J Ramsawh
    Department of Psychology, Boston University, Massachusetts 02215, USA
    J Urol 174:1395-8. 2005
    ....
  50. ncbi request reprint Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations
    Abraham Morgentaler
    J Urol 177:1954. 2007
  51. ncbi request reprint Cultural biases and scientific squabbles: the challenges to acceptance of testosterone therapy as a mainstream medical treatment
    Abraham Morgentaler
    Aging Male 10:1-2. 2007
  52. ncbi request reprint Penile rehabilitation should become the norm for radical prostatectomy patients
    John P Mulhall
    Sexual Medicine Program, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Sex Med 4:538-43. 2007
    ..At the suggestion of several SMSNA members, it was requested that this debate might be of interest to JSM readers in the form of a published controversy...
  53. ncbi request reprint Effects of chronic administration of dehydroepiandrosterone on serum testosterone levels and prostatic tissue in rats
    Ernani Luis Rhoden
    Postgraduate Course of Medical Sciences, Federal University of Rio Grande do Sul, Rua Jaragua 370 302, Bela Viste, 90450 140 Porto Alegre, RS, Brazil
    J Urol 170:2101-3. 2003
    ..We evaluated the effects of chronic administration of dehydroepiandrosterone (DHEA) on serum total testosterone and DHEA sulfate (DHEAS), prostatic weight and histological features in the rat...